Valuation: Axsome Therapeutics, Inc.

Market Cap 12.05B 10.58B 9.85B 9.06B 16.98B 1,151B 17.27B 117B 45.74B 571B 45.25B 44.27B 1,973B P/E 2026 *
-114x
P/E 2027 * 42.2x
Enterprise Value 11.94B 10.48B 9.76B 8.98B 16.83B 1,141B 17.11B 116B 45.32B 566B 44.83B 43.86B 1,955B EV / Sales 2026 *
12.2x
EV / Sales 2027 * 7.3x
Free-Float
84.36%
Yield 2026 *
-
Yield 2027 * -
1 day-1.35%
1 week-3.53%
Current month-5.56%
1 month-4.13%
3 months+25.66%
6 months+24.77%
Current year+26.56%
1 week 229.58
Extreme 229.58
245.5
1 month 221.21
Extreme 221.21
252.6
Current year 152.28
Extreme 152.28
260.19
1 year 96.09
Extreme 96.09
260.19
3 years 55.02
Extreme 55.02
260.19
5 years 19.38
Extreme 19.38
260.19
10 years 1.94
Extreme 1.94
260.19
Manager TitleAgeSince
Chief Executive Officer 57 2012-01-11
Director of Finance/CFO 51 2018-05-15
Chief Operating Officer 42 2014-03-31
Director TitleAgeSince
Chairman 57 2012-01-11
Director/Board Member 64 2014-11-30
Director/Board Member 58 2014-11-30
Date Insider Type Main position Quantity % Market Cap.
7/1/26 Fiscal year

Chief Executive Officer

148,998 0.2895%
6/11/26 Sell

Director

-286 0.0006%
6/10/26 Sell

Director

-300 0.0006%
Change 5-day change 1-year change 3-year change Capi.($)
-1.62%-3.53%+130.21%+194.57% 12.05B
+0.06%+7.10%+24.95%-6.00% 70.73B
+0.28%+3.12%+35.58%+211.60% 54.27B
-4.52%+47.90%+47.90%+47.90% 49.28B
+7.15%+5.51%-52.67%-51.99% 39.94B
+4.96%+9.25%+68.90%-20.05% 30.36B
-2.67%+9.38%+63.68%+98.76% 25.96B
-1.81%-4.32%+70.12%-52.78% 22.14B
-0.22%-2.66%-4.47%+145.08% 19.96B
-1.10%+2.37%+82.69%+141.70% 16.77B
Average +0.04%+1.68%+46.69%+70.88% 34.15B
Weighted average by Cap. +0.22%+2.39%+35.49%+57.83%

Financials

2026 *2027 *
Net sales 979M 859M 800M 736M 1.38B 93.52B 1.4B 9.49B 3.71B 46.38B 3.68B 3.6B 160B 1.6B 1.4B 1.3B 1.2B 2.25B 153B 2.29B 15.48B 6.06B 75.64B 5.99B 5.86B 261B
Net income -107M -94.16M -87.69M -80.65M -151M -10.25B -154M -1.04B -407M -5.08B -403M -394M -17.56B 309M 271M 253M 232M 436M 29.53B 443M 3B 1.17B 14.65B 1.16B 1.14B 50.6B
Net Debt -111M -97.15M -90.46M -83.21M -156M -10.58B -159M -1.07B -420M -5.24B -416M -407M -18.12B -394M -346M -322M -296M -555M -37.62B -564M -3.82B -1.49B -18.66B -1.48B -1.45B -64.46B
Logo Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company focused on developing medicines for people impacted by central nervous system (CNS) conditions. Its commercial products include AUVELITY, SUNOSI, and SYMBRAVO. It is also advancing pipeline of novel product candidates in early- to late-stage development addressing a broad range of serious neurological and psychiatric conditions. Its product pipelines include AXS-05, AXS-12, and AXS-14. Its lead product candidate, AXS-05 (dextromethorphan-bupropion), is developed for the treatment of Alzheimer’s disease (AD) agitation and smoking cessation. Its AXS-12 (reboxetine) is a novel, oral, potent, highly selective investigational norepinephrine reuptake inhibitor (NRI) and cortical dopamine modulator being developed for the treatment of narcolepsy. Its AXS-14 (esreboxetine) is a novel, oral, potent, highly selective investigational NRI being developed for the management of fibromyalgia.
Employees
1,220
Date Price Change Volume
26-07-29 $230.99 -1.37% 85,014
26-07-28 $234.20 -1.75% 404,143
26-07-27 $238.37 -1.09% 773,053
26-07-24 $241.00 -0.22% 461,989
26-07-23 $241.53 +0.80% 500,364
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
234.20USD
Average target price
282.51USD
Spread / Average Target
+20.63%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AXSM Stock